Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. 160 Health International's Research & Development for the
six
months ended in Dec. 2025 was €2.12 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €4.23 Mil.
160 Health International (FRA:O66) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
160 Health International Research & Development Related Terms
160 Health International Research & Development Historical Data
* Premium members only.
The historical data trend for 160 Health International's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
160 Health International Research & Development Chart
160 Health International Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of €4.23 Mil mean?
160 Health International (FRA:O66) has a Research & Development of €4.23 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on 160 Health International and its competitors.
Is 160 Health International's Research & Development too high?
160 Health International's current Research & Development is €4.23 Mil. Overall, 160 Health International has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does 160 Health International's Research & Development compare to MCK and COR?
160 Health International's Research & Development of €4.23 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on 160 Health International and its competitors. 160 Health International's current Research & Development is €4.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 160 Health International stock overvalued right now?
160 Health International (FRA:O66) has a current Research & Development of €4.23 Mil. The current Research & Development is €4.23 Mil. 160 Health International's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For 160 Health International (FRA:O66), the current Research & Development is €4.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
160 Health International Ltd is an experienced pharmaceutical and healthcare product wholesaler and a digital healthcare integrated service provider in China. The company offers a wide assortment of high-quality pharmaceutical and healthcare products under both wholesale and retail models, to address a spectrum of customer needs. In addition, through its online healthcare and wellness service platform, Healthcare 160 Platform. It also provide digital healthcare and wellness solutions, empowering each Platform Participants, including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry.
8GF Score
Get the complete analysis for FRA:O66
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O66 has been successfully added to your 
